{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:03Z","timestamp":1780031103177,"version":"3.53.1"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Renin-angiotensin-aldosterone system (RAAS) blockade has been a mainstay of therapy in cardiovascular and kidney disease for nearly 30 years. Despite the development of multiple drug classes designed to intervene along the RAAS pathway, the residual risk for the totality of adverse cardiorenal outcomes (cardiorenal disease) remains substantial. Dysregulation of aldosterone biosynthesis has pathophysiological consequences that are associated with cardiovascular and kidney damage. Aldosterone synthase inhibitors (ASi) provide a mechanism to decrease aldosterone production. These agents may help to reduce residual risk in cardiorenal disease. Preliminary evidence from ASi clinical trials is encouraging, with demonstrated efficacy in improving blood pressure control and decreasing albuminuria in chronic kidney disease. Their therapeutic potential in improving cardiorenal outcomes is being investigated further in ongoing phase III trials where ASi agents are given as monotherapy or with an SGLT2 inhibitor, and these data will be available over the coming months and years. ASi agents may be a new evidence-based addition to the cardiorenal drug armamentarium.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1845339","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:48:42Z","timestamp":1780030122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Kausik","family":"Umanath","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Indiana University School of Medicine","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah Health","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine","place":["Durham, NC, United States"]},{"name":"Duke Clinical Research Institute","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","volume-title":"Physiology, Renin Angiotensin System","author":"Fountain","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.mcna.2009.02.014","article-title":"The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress","volume":"93","author":"Manrique","year":"2009","journal-title":"Med Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"99","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/postgradmedj-2016-134045","article-title":"The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future","volume":"93","author":"Orsborne","year":"2017","journal-title":"Postgrad Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jcpt.13243","article-title":"Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: a meta-analysis of randomized controlled trials","volume":"45","author":"Feng","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1159\/000541939","article-title":"Angiotensin receptor-neprilysin inhibitor for chronic kidney disease: strategies for renal protection","volume":"49","author":"Hishida","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e28608","DOI":"10.7759\/cureus.28608","article-title":"Efficacy of direct renin inhibitors in slowing down the progression of diabetic kidney disease: a meta-analysis","volume":"14","author":"Akbariromani","year":"2022","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1338044","DOI":"10.3389\/fphar.2024.1338044","article-title":"Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD015588","DOI":"10.1002\/14651858.CD015588.pub2","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/ehjcvp\/pvae049","article-title":"New ways of mitigating aldosterone in cardiorenal disease","volume":"10","author":"G\u00f6tzinger","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1159\/000542621","article-title":"Aldosterone synthase inhibitors for cardiorenal protection: ready for prime time?","volume":"49","author":"Mazzieri","year":"2024","journal-title":"Kidney Blood Press. Res"},{"key":"B21","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1210\/jc.2003-030490","article-title":"50th Anniversary of aldosterone","volume":"88","author":"Williams","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1152\/advan.00051.2001","article-title":"Aldosterone","volume":"26","author":"Booth","year":"2002","journal-title":"Adv Physiol Educ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.3390\/ijms24065782","article-title":"Molecular and epigenetic control of aldosterone synthase, CYP11B2 and 11-hydroxylase, CYP11B1","volume":"24","author":"Takeda","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-023-03566-6","article-title":"Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone","volume":"83","author":"Xu","year":"2024","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1578117","DOI":"10.3389\/fphar.2025.1578117","article-title":"Prediction of pharmacokinetic\/pharmacodynamic properties of aldosterone synthase inhibitors at drug discovery stage using an artificial intelligence-physiologically based pharmacokinetic model","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","article-title":"Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta)","volume":"264","author":"Mornet","year":"1989","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/HYPERTENSIONAHA.121.17615","article-title":"Aldosterone synthase structure with cushing disease drug LCI699 highlights avenues for selective CYP11B drug design","volume":"78","author":"Brixius-Anderko","year":"2021","journal-title":"Hypertension"},{"key":"B29","doi-asserted-by":"publisher","first-page":"T107","DOI":"10.1530\/JOE-16-0659","article-title":"30 Years of the mineralocorticoid receptor: nongenomic effects via the mineralocorticoid receptor","volume":"234","author":"Ruhs","year":"2017","journal-title":"J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrneph.2009.228","article-title":"Aldosterone \u2018escape\u2019 vs \u2018breakthrough\u2019","volume":"6","author":"Schrier","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41440-022-00913-4","article-title":"Aldosterone breakthrough from a pharmacological perspective","volume":"45","author":"Mogi","year":"2022","journal-title":"Hypertens Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.3390\/ijms24065370","article-title":"The effect of aldosterone on cardiorenal and metabolic systems","volume":"24","author":"Otsuka","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.cjca.2023.08.035","article-title":"Revising the roles of aldosterone in vascular physiology and pathophysiology: from electocortin to baxdrostat","volume":"39","author":"Feldman","year":"2023","journal-title":"Can J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"B38","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"H813","DOI":"10.1152\/ajpheart.00113.2003","article-title":"Aldosteronism: an immunostimulatory state precedes proinflammatory\/fibrogenic cardiac phenotype","volume":"285","author":"Gerling","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/ijms26020540","article-title":"Non-hypertensive effects of aldosterone","volume":"26","author":"Ekman","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/978-981-13-8871-2_15","article-title":"Role of aldosterone in renal fibrosis","volume":"1165","author":"Shrestha","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0203823","DOI":"10.1371\/journal.pone.0203823","article-title":"The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice","volume":"13","author":"Sogawa","year":"2018","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0145946","DOI":"10.1371\/journal.pone.0145946","article-title":"Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats","volume":"11","author":"Mart\u00edn-Fern\u00e1ndez","year":"2016","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1161\/01.RES.0000025268.10302.0C","article-title":"Osteopontin plays an important role in the development of medial thickening and neointimal formation","volume":"91","author":"Isoda","year":"2002","journal-title":"Circ Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1172\/JCI40205","article-title":"Placental growth factor mediates aldosterone-dependent vascular injury in mice","volume":"120","author":"Jaffe","year":"2010","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"30087","DOI":"10.1074\/jbc.M109.030718","article-title":"Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1)","volume":"284","author":"Stow","year":"2009","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"F1287","DOI":"10.1152\/ajprenal.00017.2008","article-title":"Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells","volume":"294","author":"Huang","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/en.2002-220956","article-title":"Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes","volume":"144","author":"Chun","year":"2003","journal-title":"Endocrinology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e15985","DOI":"10.1097\/MD.0000000000015985","article-title":"Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis","volume":"98","author":"Wu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"646933","DOI":"10.3389\/fendo.2021.646933","article-title":"New-onset atrial fibrillation in patients with primary aldosteronism receiving different treatment strategies: systematic review and pooled analysis of three studies","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1530\/EJE-22-0375","article-title":"Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis","volume":"187","author":"Chen","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e038714","DOI":"10.1161\/JAHA.124.038714","article-title":"Major adverse cardiovascular events in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a systematic review and meta-analysis","volume":"14","author":"Huang","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B59","doi-asserted-by":"publisher","first-page":"102615","DOI":"10.1016\/j.cpcardiol.2024.102615","article-title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials","volume":"49","author":"Pamporis","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"B64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12872-024-04103-7","article-title":"Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis","volume":"24","author":"Elshahat","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B65","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub4","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"967317","DOI":"10.3389\/fphar.2022.967317","article-title":"Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1476029","DOI":"10.3389\/fcvm.2024.1476029","article-title":"A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist","volume":"11","author":"Zhai","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/bcp.15713","article-title":"CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers","volume":"89","author":"Mulatero","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e70000","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1007\/s00210-025-03838-0","article-title":"Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers","volume":"398","author":"Schulze","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1237583","DOI":"10.3389\/fphar.2023.1237583","article-title":"Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials","volume":"14","author":"Du","year":"2024","journal-title":"Front Pharmacol"},{"key":"B76","year":""},{"key":"B77","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2022","journal-title":"Clin Kidney J"},{"key":"B78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1097\/MS9.0000000000001180","article-title":"Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis","volume":"85","author":"Yasmin","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B82","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41371-023-00889-9","article-title":"Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis","volume":"38","author":"Sun","year":"2024","journal-title":"J Hum Hypertens"},{"key":"B83","year":""},{"key":"B84","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1093\/ndt\/gfaf119","article-title":"Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial","volume":"40","author":"Mark","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B88","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"key":"B89","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B92","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"B93","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"B95","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"M\u00e9nard","year":"2014","journal-title":"J Transl Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/DDDT.S315359","article-title":"Clinical utility of osilodrostat in Cushing\u2019s disease: review of currently available literature","volume":"17","author":"Perosevic","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"B97","year":""},{"key":"B98","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"B99","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.jpet.2025.103649","article-title":"Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys; contrasting effects of once versus twice daily dosing","volume":"392","author":"Weldon","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"B100","author":"Kumbhani","year":""},{"key":"B101","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202544j6mmcr","article-title":"Lorundrostat, a novel aldosterone synthase inhibitor (ASi), in participants with uncontrolled hypertension, CKD, and albuminuria: results from Explore-CKD (FR-OR091)","volume":"36","author":"Weir","year":"2025","journal-title":"JASN"},{"key":"B104","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.eclinm.2024.102576","article-title":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","volume":"71","author":"Mulatero","year":"2024","journal-title":"eClinicalMed"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"B107","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1681\/ASN.2024fbrh9bc4","article-title":"Effect of baxdrostat on albuminuria in treatment-resistant hypertension (SA\u2013PO353)","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"B109","year":""},{"key":"B110","year":""},{"key":"B111","year":""},{"key":"B112","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B114","year":""},{"key":"B115","year":""},{"key":"B116","year":""},{"key":"B117","year":""},{"key":"B118","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12882-024-03833-2","article-title":"Cardio-renal protective effect and safety of sodium-glucose cotransporter 2 inhibitors for chronic kidney disease patients with eGFR < 60\u2005mL\/min\/1.73 m2: a systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Nephrol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.5646\/ch.2025.31.e41","article-title":"Efficacy and safety of selective aldosterone synthase inhibitors in uncontrolled hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Louat","year":"2025","journal-title":"Clin Hypertens"},{"key":"B125","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/openhrt-2025-003535","article-title":"Comparative efficacy and safety of aldosterone synthase inhibitors in hypertension: a Bayesian network meta-analysis of randomised controlled rials","author":"Dewi","year":"2025","journal-title":"Open Heart"},{"key":"B126","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1845339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:48:48Z","timestamp":1780030128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1845339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":126,"alternative-id":["10.3389\/fcvm.2026.1845339"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1845339","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1845339"}}